Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CHAMPIONS ONCOLOGY, INC.

Get SEC filing alerts via email and in your feed for CHAMPIONS ONCOLOGY, INC.

CSBR

CHAMPIONS ONCOLOGY, INC.

About CHAMPIONS ONCOLOGY, INC.

Champions Oncology, Inc. is a technology-driven oncology research company specializing in drug discovery and development. It operates a proprietary bank of approximately 1,500 Patient Derived Xenograft (PDX) tumor models used in advanced in vivo and ex vivo pharmacology platforms. Serving pharmaceutical and biotechnology companies globally, Champions offers research services, data licensing, and bioinformatics SaaS tools to accelerate cancer drug development through integrated computational and experimental platforms.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CHAMPIONS ONCOLOGY, INC.

1
1
CHAMPIONS ONCOLOGY, INC. Champions Oncology Reports Decline in Profitability for Third Quarter, Net Loss of $279,000

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
CHAMPIONS ONCOLOGY, INC. Champions Oncology Reports 11.5% Revenue Growth but Net Loss for Quarter Ending October 31, 2025

Via official filing (AI summary) | 6 months ago | 0 comments

3
1
CHAMPIONS ONCOLOGY, INC. Champions Oncology Reports Revenue Decline and Net Loss for Quarter Ending July 31, 2025

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
CHAMPIONS ONCOLOGY, INC. Champions Oncology Reports 13.5% Revenue Growth and Net Income Turnaround for Fiscal Year Ending April 30, 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
CHAMPIONS ONCOLOGY, INC. Champions Oncology Reports 41.8% Revenue Growth and Net Income Turnaround in Latest 10-Q

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CHAMPIONS ONCOLOGY, INC. Champions Oncology Reports Net Income of $728,000 and Revenue Growth for Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
CHAMPIONS ONCOLOGY, INC. Champions Oncology Reports Improved Financial Performance in Q2 2024

Via official filing (AI summary) | over 1 year ago | 0 comments